CABALETTA BIO, INC. Comprehensive Income
CABALETTA BIO, INC. (CABA) reported Comprehensive Income of -$51.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$51.02M.
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$43.54M.
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$41.92M.
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$44.84M.
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$167.83M.
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$115.90M.
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$67.59M.
- CABALETTA BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$53.02M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$51.02M 10-Q · filed 2026-08-13 | -$94.56M 10-Q · filed 2026-08-13 | -$136.47M derived: sum of 3 quarters · filed 2026-08-13 | -$181.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$43.54M 10-Q · filed 2026-05-14 | -$85.46M derived: sum of 2 quarters · filed 2026-05-14 | -$130.30M derived: sum of 3 quarters · filed 2026-05-14 | -$175.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$41.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$86.76M derived: sum of 2 quarters · filed 2026-03-23 | -$131.89M derived: sum of 3 quarters · filed 2026-08-13 | -$167.83M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$44.84M 10-Q · filed 2025-11-10 | -$89.97M derived: sum of 2 quarters · filed 2026-08-13 | -$125.91M 10-Q · filed 2025-11-10 | -$158.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$45.13M 10-Q · filed 2026-08-13 | -$81.07M 10-Q · filed 2026-08-13 | -$113.66M derived: sum of 3 quarters · filed 2026-08-13 | -$144.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$35.94M 10-Q · filed 2026-05-14 | -$68.53M derived: sum of 2 quarters · filed 2026-05-14 | -$99.13M derived: sum of 3 quarters · filed 2026-05-14 | -$126.72M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$32.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$63.19M derived: sum of 2 quarters · filed 2026-03-23 | -$90.78M derived: sum of 3 quarters · filed 2026-03-23 | -$115.90M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$30.60M 10-Q · filed 2025-11-10 | -$58.19M derived: sum of 2 quarters · filed 2025-11-10 | -$83.32M 10-Q · filed 2025-11-10 | -$104.09M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$27.59M 10-Q · filed 2025-08-07 | -$52.72M 10-Q · filed 2025-08-07 | -$73.50M derived: sum of 3 quarters · filed 2025-08-07 | -$89.96M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$25.12M 10-Q · filed 2025-05-15 | -$45.90M derived: sum of 2 quarters · filed 2025-05-15 | -$62.37M derived: sum of 3 quarters · filed 2025-05-15 | -$76.86M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$20.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$37.24M derived: sum of 2 quarters · filed 2025-03-31 | -$51.73M derived: sum of 3 quarters · filed 2025-03-31 | -$67.59M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$16.47M 10-Q · filed 2024-11-14 | -$30.96M derived: sum of 2 quarters · filed 2024-11-14 | -$46.81M 10-Q · filed 2024-11-14 | -$62.29M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$14.49M 10-Q · filed 2024-08-08 | -$30.30M 10-Q · filed 2024-08-08 | -$45.83M derived: sum of 3 quarters · filed 2024-08-08 | -$57.21M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$15.81M 10-Q · filed 2024-05-15 | -$31.34M derived: sum of 2 quarters · filed 2024-05-15 | -$42.72M derived: sum of 3 quarters · filed 2024-05-15 | -$55.73M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$26.92M derived: sum of 2 quarters · filed 2024-03-21 | -$39.92M derived: sum of 3 quarters · filed 2024-03-21 | -$53.02M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$11.39M 10-Q · filed 2023-11-09 | -$24.39M derived: sum of 2 quarters · filed 2023-11-09 | -$37.49M 10-Q · filed 2023-11-09 | -$51.37M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$13.01M 10-Q · filed 2023-08-10 | -$26.11M 10-Q · filed 2023-08-10 | -$39.99M derived: sum of 3 quarters · filed 2023-08-10 | -$51.55M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$13.10M 10-Q · filed 2023-05-11 | -$26.98M derived: sum of 2 quarters · filed 2023-05-11 | -$38.54M derived: sum of 3 quarters · filed 2023-05-11 | -$49.68M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$13.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$25.44M derived: sum of 2 quarters · filed 2023-03-16 | -$36.58M derived: sum of 3 quarters · filed 2023-03-16 | -$46.29M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$11.56M 10-Q · filed 2022-11-10 | -$22.70M derived: sum of 2 quarters · filed 2022-11-10 | -$32.41M 10-Q · filed 2022-11-10 | -$41.72M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$11.14M 10-Q · filed 2022-08-11 | -$20.84M 10-Q · filed 2022-08-11 | -$30.16M derived: sum of 3 quarters · filed 2022-08-11 | -$38.55M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$9.71M 10-Q · filed 2022-05-12 | -$19.02M derived: sum of 2 quarters · filed 2022-05-12 | -$27.41M derived: sum of 3 quarters · filed 2022-05-12 | -$35.55M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$9.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$17.71M derived: sum of 2 quarters · filed 2022-03-17 | -$25.85M derived: sum of 3 quarters · filed 2022-03-17 | -$33.33M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$8.39M 10-Q · filed 2021-11-01 | -$16.53M derived: sum of 2 quarters · filed 2021-11-01 | -$24.02M 10-Q · filed 2021-11-01 | -$29.42M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | -$8.14M 10-Q · filed 2021-08-05 | -$15.63M 10-Q · filed 2021-08-05 | -$21.03M derived: sum of 3 quarters · filed 2021-08-05 | -$25.68M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$7.49M 10-Q · filed 2021-05-03 | -$12.89M derived: sum of 2 quarters · filed 2021-05-03 | -$17.54M derived: sum of 3 quarters · filed 2021-05-03 | -$20.90M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$10.05M derived: sum of 2 quarters · filed 2021-03-16 | -$13.41M derived: sum of 3 quarters · filed 2021-03-16 | -$22.27M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$4.65M 10-Q · filed 2020-11-10 | -$8.01M derived: sum of 2 quarters · filed 2020-11-10 | -$16.87M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$3.36M 10-Q · filed 2020-08-06 | -$12.22M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |